Secondary prevention medicine | Non-adherence rate prior to clinic | Non-adherence rate 3–6 months post-clinic | Relative reduction in non-adherence | P value |
ACE inhibitor /ARB | 27/178 (15.2%) | 10/130 (7.7%) | 49.3% | 0.046 |
Beta blocker | 23/169 (13.6%) | 5/119 (4.2%) | 69.1% | 0.008 |
Statin | 39/181 (21.5%) | 8/127 (6.3%) | 70.8% | <0.001 |
Clopidogrel/prasugrel/ticagrelor | 32/173 (18.5%) | 7/126 (5.6%) | 69.7% | 0.001 |
Aspirin | 24/176 (13.6%) | 10/128 (7.8%) | 42.6% | 0.112 |
ARB, angiotensin receptor blocker.ACE, Angiotensin-Converting Enzyme.